Arch Therapeutics, Inc. financial data

Symbol
ARTH on OTC
Industry
Surgical & Medical Instruments & Apparatus
Location
235 Walnut Street, Suite 6, Framingham, MA
State of incorporation
NV
Fiscal year end
September 30
Former names
ALMAH,INC (to 5/24/2013)
Latest financial report
10-Q - Q2 2024 - Aug 19, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 14.2 % -58.9%
Quick Ratio 11.3 % -51.2%
Debt-to-equity -122 % +23.8%
Return On Equity 121 % +15.5%
Return On Assets -730 % -138%
Operating Margin -3.19K % +76.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4.44M shares
Common Stock, Shares, Outstanding 4.44M shares +246%
Entity Public Float 4M USD -81.8%
Common Stock, Value, Issued 4.44K USD +246%
Weighted Average Number of Shares Outstanding, Basic 4.44M shares +247%
Weighted Average Number of Shares Outstanding, Diluted 4.44M shares +247%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 148K USD +292%
Cost of Revenue 89.5K USD +62.7%
Research and Development Expense 765K USD +8.9%
Costs and Expenses 4.87M USD -6.25%
Operating Income (Loss) -4.72M USD +8.43%
Nonoperating Income (Expense) -4.63M USD -473%
Net Income (Loss) Attributable to Parent -12.3M USD -91.2%
Earnings Per Share, Basic -1.04 USD/shares +79.6%
Earnings Per Share, Diluted -1.44 USD/shares -1.41%

Balance Sheet

Label TTM Value / Value Unit Change %
Inventory, Net 1.32M USD -4.53%
Assets, Current 1.39M USD -10.8%
Property, Plant and Equipment, Net 3.01K USD +314%
Operating Lease, Right-of-Use Asset 0 USD
Other Assets, Noncurrent 3.5K USD 0%
Assets 1.4M USD -10.7%
Accounts Payable, Current 2.92M USD +18%
Liabilities, Current 14M USD +45.7%
Liabilities 9.47M USD +39.3%
Retained Earnings (Accumulated Deficit) -72.6M USD -21.8%
Stockholders' Equity Attributable to Parent -12.6M USD -56.7%
Liabilities and Equity 1.4M USD -10.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -863K USD -32.7%
Net Cash Provided by (Used in) Financing Activities 846K USD
Common Stock, Shares Authorized 350M shares +2817%
Common Stock, Shares, Issued 4.44M shares +246%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -16.9K USD +97.7%
Deferred Tax Assets, Valuation Allowance 17.6M USD +12.6%
Deferred Tax Assets, Gross 17.6M USD +12.6%
Operating Lease, Liability 0 USD
Depreciation 1.95K USD -36.2%
Property, Plant and Equipment, Gross 33.8K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 12.9M USD +12.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares
Additional Paid in Capital 48.9M USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Interest Expense 3.72M USD +126%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares